With regard to therapeutic avenues, FBPase‐1 inhibitor‐1 functions as an allosteric inhibitor of FBP,201 while FBPase‐IN‐1 has been identified as another FBP inhibitor with the capability to ameliorate hyperglycemia and glucose intolerance in Type 2 diabetes.202. Here, FBP1 is linked to type 2 diabetes mellitus.